Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclibfulvestrant (PF) in the treatment of metastatic HR1, HER2-breast cancer. Indirect comparisons with network meta-analysis for daily clinical practice
ANNALS OF ONCOLOGY(2017)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要